Thumbnail Image
Publication

CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial.

Gleeson, M
; 
Peckitt, C
; 
To, Y
; 
Edwards, L
; 
Oates, J
; 
Wotherspoon, A
; 
Attygalle, A
; 
Zerizer, I
; 
Sharma, B
; 
Chua, S
... show 10 more
Citations
Altmetric:
Abstract
Outcomes with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) or CHOP-like chemotherapy in peripheral T-cell lymphoma are poor. We investigated whether the regimen of gemcitabine, cisplatin, and methylprednisolone (GEM-P) was superior to CHOP as front-line therapy in previously untreated patients.
Authors
Gleeson, M
Peckitt, C
To, Y
Edwards, L
Oates, J
Wotherspoon, A
Attygalle, A
Zerizer, I
Sharma, B
Chua, S
Begum, R
Chau, I
Johnson, P
Ardeshna, K
Hawkes, E
Macheta, M
Collins, G
Radford, John A
Forbes, A
Hart, A
Montoto, S
McKay, P
Benstead, K
Morley, N
Kalakonda, N
Hasan, Y
Turner, D
Cunningham, D
Affiliation
The Royal Marsden NHS Foundation Trust, London and Surrey, UK
Description
Lymphoma Research Team
Date
2018-05
Publisher
Collections
All Christie Publications
Show all metadata
Files
Thumbnail Image
Full text, Open Access article
Adobe PDF, 341.39 KB
Keywords
Type
Article
Citation
CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. 2018, 5(5): e190-e200 Lancet Haematol
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/621049
Embedded videos